| アイテムタイプ |
学術雑誌論文 / Journal Article(1) |
| 公開日 |
2024-12-11 |
| タイトル |
|
|
タイトル |
Current and Future PET Imaging for Multiple Myeloma |
|
言語 |
en |
| 言語 |
|
|
言語 |
eng |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| 著者 |
Ishibashi Mariko
Takahashi Miwako
Yamaya Taiga
Yoichi Imai
|
| 抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Positron emission tomography (PET) is an imaging modality used for the noninvasive assessment of tumor staging and response to therapy. PET with 18F labeled fluorodeoxyglucose (18F-FDG PET) is widely used to assess the active and inactive lesions in patients with multiple myeloma (MM). Despite the availability of 18F-FDG PET for the management of MM, PET imaging is less sensitive than next-generation flow cytometry and sequencing. Therefore, the novel PET radiotracers 64Cu-LLP2A, 68Ga-pentixafor, and 89Zr-daratumumab have been developed to target the cell surface antigens of MM cells. Furthermore, recent studies attempted to visualize the tumorinfiltrating lymphocytes using PET imaging in patients with cancer to investigate their prognostic effect; however, these studies have not yet been performed in MM patients. This review summarizes the recent studies on PET with 18F-FDG and novel radiotracers for the detection of MM and the resulting preclinical research using MM mouse models and clinical studies. Novel PET technologies may be useful for developing therapeutic strategies for MM in the future. |
| 書誌情報 |
Life
巻 13,
号 8,
p. 1701-1-1701-14,
発行日 2023-08
|
| 出版者 |
|
|
出版者 |
MDPI AG |
| ISSN |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
2075-1729 |
| DOI |
|
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
10.3390/life13081701 |
